Compare
Phibro Animal Health Corp vs Perrigo Co PLC vs Sinovac Biotech Ltd vs Organon & Co.
| Latest fiscal year | Phibro Animal Health Corp PAHC | Perrigo Co PLC PRGO | Sinovac Biotech Ltd SVA | Organon & Co. OGN |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.52B | $4.25B | $386.01M | $6.22B |
| Revenue growth (YoY) | +17.1% | -2.8% | +6.8% | -2.9% |
| Gross margin | 33.8% | 35.1% | 67.9% | 53.3% |
| Operating margin | 12.8% | -26.4% | -127.0% | n/a |
| Net margin | 6.6% | -33.5% | -51.5% | 3.0% |
| Net income | $99.72M | -$1.43B | -$198.84M | $187.00M |
| EPS (Diluted) | $2.43 | -$10.29 | -$0.83 | $0.72 |
| Operating cash flow | $68.95M | $238.50M | -$512.18M | $700.00M |
| Free cash flow | $9.87M | $145.10M | -$561.10M | $538.00M |
| Cash & equivalents | $61.42M | n/a | $488.25M | $574.00M |
| Total assets | $1.50B | $8.54B | $8.54B | $12.87B |
| Total liabilities | $1.12B | $5.60B | $2.15B | $12.12B |
| Shareholders' equity | $385.48M | $2.94B | $6.40B | $752.00M |
| Return on year-end equity | 25.9% | -48.6% | -3.1% | 24.9% |
| Shares outstanding | n/a | 137.60M | 71.86M | 260.32M |
Revenue, most recent five fiscal years
| Fiscal year | Phibro Animal Health Corp | Perrigo Co PLC | Sinovac Biotech Ltd | Organon & Co. |
|---|---|---|---|---|
| Latest | $1.52B Ended 2026-06-30 | $4.25B Ended 2025-12-31 | $386.01M Ended 2025-12-31 | $6.22B Ended 2025-12-31 |
| 1 year earlier | $1.30B Ended 2025-06-30 | $4.37B Ended 2024-12-31 | $361.37M Ended 2024-12-31 | $6.40B Ended 2024-12-31 |
| 2 years earlier | $1.02B Ended 2024-06-30 | $4.66B Ended 2023-12-31 | $470.17M Ended 2023-12-31 | $6.26B Ended 2023-12-31 |
| 3 years earlier | $977.89M Ended 2023-06-30 | $4.45B Ended 2022-12-31 | $1.47B Ended 2022-12-31 | $6.17B Ended 2022-12-31 |
| 4 years earlier | $942.26M Ended 2022-06-30 | $4.14B Ended 2021-12-31 | $19.37B Ended 2021-12-31 | $6.30B Ended 2021-12-31 |